CNS Pharmaceuticals Marks Milestone In Pursuit Of Berubicin Approval For GBM

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

  • CNS Pharmaceuticals received approval from swissethics for its potentially pivotal study of Berubicin, a novel anthracycline for the treatment of Glioblastoma Multiforme (“GBM”)
  • The approval is the first from a European Ethics Committee
  • The company, which dosed the first patients in its Berubicin program in September, has selected multiple clinical sites across the U.S., Spain, France, Italy, and Switzerland
  • CNS recently closed an $11.5 million private placement
  • It intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D programs, and for general corporate purposes

Clinical stage biotechnology company CNS Pharmaceuticals CNSP is celebrating a significant milestone as it journeys toward its potentially pivotal study of Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company announced December 2 that it had received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland (https://ibn.fm/NisfL).

The first from a European Ethics Committee, the approval partly fulfills CNS’s goal of seeing Berubicin approved for the potential treatment of GBM globally. “This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Image sourced from Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksGeneralInvestorBrandNetworkPartner Content
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!